drugset
drugset / Trial / NCT03892642

Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer

NCT03892642 ↗

Phase 1/2 Completed 18 enrolled University of Oklahoma EMD Serono · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of avelumab and Bacille Calmette-Guerin (BCG) and see what effects (good and bad) that this combination treatment has on subjects with recurrent bladder cancer.

Timeline

Start
2019-05-01
Primary completion
2021-03-23
Completion
2023-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Avelumab Monoclonal antibody — —
Subject BCG Unknown — Other

Indications

urinary bladder cancer